Choosing the best first biologic for ulcerative colitis
Part of Digestive system clinical trials.
This trial tests three different types of biologic medications to find which works best as a first treatment for moderate-to-severe ulcerative colitis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old.
- You have had ulcerative colitis for at least 3 months.
- Your ulcerative colitis is moderate to severe (score 5–9 on a standard scale).
- You have not responded well to or couldn't tolerate standard treatments like mesalamine or steroids.
- You have never taken biologic drugs or JAK inhibitors for this condition.
- You do not have other serious health issues like heart disease, blood clots, Crohn's disease, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two first-line biologic drugs for moderate to severe ulcerative colitis to see which works better and why. The goal is to help find the best biologic treatment for each patient.
This trial compares how well different combinations of drugs calm inflammation in the gut compared to single drugs. It uses tissue samples taken during a colonoscopy to see which approach works best for people with inflammatory bowel disease.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
Researchers want to see if taking two medications together (upadacitinib and vedolizumab) works better than taking just upadacitinib alone for people with moderate to severe ulcerative colitis. This is a real-world study, meaning it looks at patients being treated in normal medical practice.
This trial tests whether people with Crohn’s disease or ulcerative colitis who are currently well-controlled can safely use less-frequent anti-TNF medicine. It may help reduce treatment intensity while keeping inflammation under control.
This Phase 4 trial tests which type of biologic medicine works best as the first treatment for people with moderate-to-severe Crohn’s that mainly affects the ileum. It may help you and your care team choose a more effective first option, based on which strategy leads to better control of symptoms and intestinal inflammation.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.